Pipeline - CytomX

Advancing our pipeline

We laid the foundation for the field of conditionally activated biologics, and our pipeline of Probody® therapeutics is built on a robust portfolio of proprietary and patented technology. Rooted in innovation and differentiation, and driven by our mission and vision, we are advancing an oncology pipeline of Probody therapeutics through our own bold science and partnerships with some of the world’s leading biopharmaceutical companies.

PROBODY^® Platform Drives Highly Differentiated Pipeline

Product Candidate(s)

Indication(s)

Preclinical

Phase 1

Phase 1 Expansion

Commercial Rights*

Clinical Pipeline

❯ Varseta-MEpCAM Topo-1 ADC

3L+ metastatic CRC (mCRC)

Varseta-M + bevacizumab

2L/3L mCRC

Trials anticipated to begin in 2H 2026

Varseta-M + bevacizumab + chemotherapy

2L mCRC**

Trials anticipated to begin in 2H 2026

Varseta-M

Additional EpCAM+ indications**

❯ CX-801(IFN-α2b)

Advanced Melanoma

Preclinical Programs

CX-908(P-Cadherin x CD3)

Solid Tumors

Probody TCBs

Solid Tumors

PROBODY® mRNAs

Oncology & Non-Oncology

Probody^® Modality:

ADCs

TCBs

mRNA

Immunotherapy

Undisclosed

Lead candidates

We are utilizing our Probody^® platform to develop potential best-in-class therapies against clinically validated targets and potential first-in-class therapeutics against novel, difficult-to-treat targets.

We believe our Probody therapeutics have the potential to:

Create or widen therapeutic window – the balance between a therapy’s dose that is effective without causing unacceptable toxicity
Enable new combinations of drugs previously not possible due to toxicities
Expand the universe of viable therapeutic targets by opening “undruggable” target space
Make new treatment options possible for more patients

Varseta-M (CX-2051)

CX-2051 is a conditionally activated ADC directed toward the epithelial cell adhesion molecule (EpCAM), with potential applicability across multiple EpCAM-expressing epithelial cancers. EpCAM is a validated anti-cancer target for which systemic therapies not yet been developed due to widespread expression on normal tissues. CX-2051 is designed to open a therapeutic window for a systemically administered anti-EpCAM ADC. CX-2051 is currently in a Phase 1 dose-escalation study in patients with advanced colorectal cancer (CRC); positive interim Phase 1 clinical data in patients with CRC was reported in May 2025; additional data is anticipated in the first quarter of 2026.

CX-801
(Interferon alpha-2b Probody cytokine)

CX-801 is a wholly-owned interferon (IFN) alpha-2b Probody® therapeutic. Interferons are approved anti-cancer therapies but are limited by narrow therapeutic windows. Based on preclinical studies, CX-801 demonstrated a wide therapeutic index with an enhanced tolerability profile versus unmasked IFN, without compromising its potent antitumor effects. CX-801 has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. The drug candidate is currently in a Phase 1 dose-escalation study in patients with metastatic melanoma; initial Phase 1 translational and biomarker data were presented at a scientific symposium in November 2025.

Clinical trials

Two of our drug candidates are currently in clinical trials, investigating their potential utility in advanced or recurrent cancers.

Learn More

Access information for healthcare providers & patients